MedPath

Tagged News

Singapore Opens New Clinical Trial Centre for Precision Geromedicine at NUS Medicine

Precision Medicine
  • Singapore has unveiled a 350-square-meter Clinical Trial Centre at NUS Medicine dedicated to translating geroscience into clinical practice through precision geromedicine approaches.
  • The facility employs a multimodal approach combining biomarker-driven diagnostics, digital monitoring, and systems biology to tailor interventions based on individual biological age and health trajectories.
  • Current trials include PROMETHEUS combining exercise and lifestyle coaching, SIRT6 Activator exploring DNA-repair potential of fucoidan, and CEDIRA examining multivitamin effects on biological age.
  • The centre integrates research with education to train clinician-scientists while addressing the gap between biomarker discovery and real-world intervention in aging research.

Adial Pharmaceuticals Completes Validation of Genetic Test for Alcohol Use Disorder Treatment

Precision Medicine
  • Adial Pharmaceuticals successfully validated a cheek swab genetic test with Genomind to identify patients suitable for AD04 therapy in upcoming Phase 3 trials.
  • The test identifies specific genetic variants in the serotonergic system, with the AG+ biomarker present in approximately 14% of the general population.
  • FDA confirmed the genetic test poses Non-Significant Risk for Phase 3 studies, eliminating the need for an Investigational Device Exemption application.
  • The validated assay demonstrated 100% concordance across all single nucleotide polymorphism testing and can be easily administered in physician offices or at home.

University of Washington Develops Programmable Proteins with Boolean Logic for Precision Drug Delivery

Precision Medicine
  • University of Washington researchers have engineered programmable proteins with autonomous decision-making capabilities that use Boolean logic to target specific disease sites based on multiple biomarker combinations.
  • The innovative protein tails can respond to up to five different biomarkers simultaneously, significantly improving targeting precision compared to single-biomarker approaches that often cause off-target effects.
  • Advanced synthetic biology techniques now enable production of these complex logic-responsive proteins in weeks rather than months, making the technology scalable for clinical applications.
  • The platform shows particular promise for cancer therapy by recognizing intricate tumor biomarker landscapes while sparing healthy tissue, potentially transforming precision medicine approaches.

FairJourney Biologics Appoints Former Evotec CEO Werner Lanthaler to Lead Antibody Discovery Platform

Drug DiscoveryPrecision MedicineLeadership Change
  • FairJourney Biologics has appointed Dr. Werner Lanthaler, former 15-year CEO of Evotec SE, as its new Chief Executive Officer to strengthen the company's global position in antibody discovery and development.
  • Founder António Parada will transition from CEO to the Supervisory Board after nearly 14 years of leadership, focusing on driving the company's innovation strategy.
  • Lanthaler emphasized that shared data- and AI-driven innovation platforms will be critical to accelerating drug discovery while reducing development timelines and costs.
  • The leadership change positions FairJourney Biologics to deliver significant efficiency gains through its entire "Gene to Clone" process for pharmaceutical partners.

Ireland Launches Phase 2 of Precision Oncology Ireland Program with Expanded Investment and Clinical Focus

Precision Medicine
  • Ireland's Minister for Further and Higher Education launched Phase 2 of Precision Oncology Ireland (POI), the country's largest cancer research program focused on personalized cancer care.
  • The program represents a substantial increase in investment, scale and ambition compared to Phase 1, with enhanced clinical engagement and broader scientific scope.
  • POI-2 aims to embed research within standard cancer care and develop advanced computer simulations to design individualized diagnostic and treatment approaches for each patient.
  • The initiative brings together academics, industry partners, charities, and patients in a cross-sector collaborative model coordinated by University College Dublin's Systems Biology Ireland centre.

TruDiagnostic Receives NIH Grant to Develop Revolutionary Epigenetic Disease Prediction Platform

Precision Medicine
  • TruDiagnostic has been awarded a competitive NIH SBIR grant to develop the W-Function Epigenomic Roadmap, a breakthrough technology that maps DNA methylation changes over time to predict chronic diseases.
  • The platform leverages the world's largest longitudinal methylation dataset to identify causal epigenetic changes and filter out random noise, promising more reliable health forecasts and earlier intervention points.
  • Initial applications will target cardiovascular disease, type 2 diabetes, and mortality risk, with potential to transform precision medicine by moving from reactive to proactive healthcare strategies.
  • The technology could accelerate drug discovery by providing actionable epigenetic markers and guide personalized treatment through dynamic health tracking.

Pentixapharm's CXCR4-Targeted Radiopharmaceuticals Show Promise in Primary Aldosteronism and Bladder Cancer

Targeted TherapyPrecision Medicine
  • Pentixapharm presented extensive clinical data at EANM 2025 demonstrating [⁶⁸Ga]Ga-PentixaFor's potential to improve diagnosis in Primary Aldosteronism, a frequently underdiagnosed cause of secondary hypertension.
  • The diagnostic candidate showed high potential to significantly improve patient subtyping compared to adrenal venous sampling, the current invasive gold standard for Primary Aldosteronism.
  • First-in-human data for therapeutic candidate [¹⁷⁷Lu]Lu-PentixaTher in bladder cancer patients demonstrated initial signs of therapeutic activity, further validating CXCR4 as a clinically relevant target.
  • The findings showcase the versatility of Pentixapharm's CXCR4-targeted platform across cardiovascular, endocrine, and oncologic diseases.

Trogenix Secures $95 Million Series A to Advance Revolutionary Cancer Platform Targeting Glioblastoma

Precision Medicine
  • Trogenix completed a $95 million Series A financing led by IQ Capital to advance its Odysseus® platform for potentially curative cancer therapies.
  • The company's lead program targets glioblastoma, one of the most aggressive brain cancers with only 25% of patients surviving beyond one year.
  • Trogenix's technology combines cancer cell killing and immune stimulation using proprietary Synthetic Super Enhancers delivered via AAV vectors.
  • First patient dosing for the glioblastoma program is anticipated in Q1 2026, with additional programs targeting colorectal cancer liver metastases and other solid tumors.

Frontier Medicines Unveils DCAF2 as Novel E3 Ligase for Targeted Protein Degradation in Cancer Treatment

Precision MedicineOncology
  • Frontier Medicines published groundbreaking research in Structure journal demonstrating that DCAF2 can be harnessed as a novel E3 ligase for targeted protein degradation.
  • The study presents the first high-resolution structures of DCAF2 complex using advanced cryogenic electron microscopy and the company's proprietary Frontier™ Platform.
  • DCAF2 shows frequent overexpression in various cancer types, offering new possibilities for developing tumor-targeted protein degraders against previously undruggable proteins.
  • This discovery expands the limited repertoire of E3 ligases available for therapeutic protein degradation beyond currently used targets like VHL and cereblon.

Kihealth Secures $5M to Commercialize First-of-Its-Kind Beta Cell Apoptosis Diagnostic for Early Diabetes Detection

Precision Medicine
  • Kihealth raised $5 million in an oversubscribed seed round to commercialize its breakthrough laboratory-developed test that measures beta cell apoptosis, the earliest marker of insulin resistance and diabetes.
  • The minimally invasive blood test opens an untapped $2 billion diagnostics market with virtually no direct competitors, enabling earlier detection and intervention before overt disease develops.
  • The diagnostic platform can stratify high-risk individuals in Type 1 diabetes prevention trials and identify patients with rapid beta cell decline in Type 2 diabetes despite normal glucose levels.
  • Kihealth's test won the 2025 ADA Innovation of the Year Award, reflecting its potential to transform preventive medicine and enable more targeted therapeutic interventions.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.